v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
Total
​Total Shareholders’ Equity (Deficit) attributable to QumulusAI shareholders
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Preferred Stock
Series D Preferred Stock
Common Stock
​Additional Paid-In Capital
​Accumulated Deficit
​Non-Controlling Interests
Preferred stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2024     4,713,515 5,205,630 3,663,841 9,089,000        
Beginning of period at Dec. 31, 2024 $ (590,660) $ (590,660) $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 9,008,512 $ 408,505 $ 2,007,227 $ (33,256,873) $ 0
Common stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2024             12,835,535      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of stock (in shares)           14,000 626,670      
Issuance of common stock, net of issuance costs and preferred stock 1,780,001 1,780,001         $ 1,780,001      
Stock-based compensation 17,344 17,344           17,344    
Net income (loss) (1,822,477) (1,822,477)             (1,822,477)  
Preferred stock, shares outstanding, end of period (in shares) at Mar. 31, 2025     4,713,515 5,205,630 3,663,841 9,103,000        
End of period at Mar. 31, 2025 (615,792) (615,792) $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 9,008,512 $ 2,188,506 2,024,571 (35,079,350) 0
Common stock, shares outstanding, end of period (in shares) at Mar. 31, 2025             13,462,205      
Preferred stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2024     4,713,515 5,205,630 3,663,841 9,089,000        
Beginning of period at Dec. 31, 2024 (590,660) (590,660) $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 9,008,512 $ 408,505 2,007,227 (33,256,873) 0
Common stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2024             12,835,535      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 10,296,097                  
Preferred stock, shares outstanding, end of period (in shares) at Jun. 30, 2025     4,713,515 5,205,630 3,663,841 10,619,938        
End of period at Jun. 30, 2025 34,151,412 34,151,412 $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 12,368,078 $ 19,360,407 4,141,734 (22,960,776) 0
Common stock, shares outstanding, end of period (in shares) at Jun. 30, 2025             16,059,623      
Preferred stock, shares outstanding, beginning of period (in shares) at Mar. 31, 2025     4,713,515 5,205,630 3,663,841 9,103,000        
Beginning of period at Mar. 31, 2025 (615,792) (615,792) $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 9,008,512 $ 2,188,506 2,024,571 (35,079,350) 0
Common stock, shares outstanding, beginning of period (in shares) at Mar. 31, 2025             13,462,205      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of stock (in shares)             22,700      
Issuance of common stock, net of issuance costs and preferred stock 117,027 117,027         $ 117,027      
Issuance of preferred stock upon partial conversion of convertible note           84,756        
Issuance of preferred stock upon partial conversion of convertible note (in shares) 164,427 164,427       $ 164,427        
Issuance of Common Stock and Series D Preferred Stock for the acquisition of TCM (in shares)           1,432,182 2,574,718      
Issuance of Common Stock and Series D Preferred Stock for the acquisition of TCM 20,250,013 20,250,013       $ 3,195,139 $ 17,054,874      
Exchange of TCM stock options resulting in issuance of stock options in acquisition 1,883,955 1,883,955           1,883,955    
Stock-based compensation 233,208 233,208           233,208    
Net income (loss) 12,118,574 12,118,574             12,118,574  
Preferred stock, shares outstanding, end of period (in shares) at Jun. 30, 2025     4,713,515 5,205,630 3,663,841 10,619,938        
End of period at Jun. 30, 2025 $ 34,151,412 34,151,412 $ 5,224,127 $ 10,027,471 $ 5,990,371 $ 12,368,078 $ 19,360,407 4,141,734 (22,960,776) 0
Common stock, shares outstanding, end of period (in shares) at Jun. 30, 2025             16,059,623      
Preferred stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2025 0   0 0 0 0        
Beginning of period at Dec. 31, 2025 $ 65,292,131 62,172,216 $ 0 $ 0 $ 0 $ 0 $ 93,400,180 6,318,290 (37,546,254) 3,119,915
Common stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2025 31,367,559           31,367,559      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of stock (in shares)             172,070      
Issuance of common stock, net of issuance costs and preferred stock $ 1,932,770 1,932,770         $ 1,932,770      
Stock-based compensation 121,870 121,870           121,870    
Net income (loss) (49,616,711) (49,365,872)             (49,365,872) (250,839)
Preferred stock, shares outstanding, end of period (in shares) at Mar. 31, 2026     0 0 0 0        
End of period at Mar. 31, 2026 $ 17,730,060 14,860,984 $ 0 $ 0 $ 0 $ 0 $ 95,332,950 6,440,160 (86,912,126) 2,869,076
Common stock, shares outstanding, end of period (in shares) at Mar. 31, 2026             31,539,629      
Preferred stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2025 0   0 0 0 0        
Beginning of period at Dec. 31, 2025 $ 65,292,131 62,172,216 $ 0 $ 0 $ 0 $ 0 $ 93,400,180 6,318,290 (37,546,254) 3,119,915
Common stock, shares outstanding, beginning of period (in shares) at Dec. 31, 2025 31,367,559           31,367,559      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) $ (72,392,917)                  
Preferred stock, shares outstanding, end of period (in shares) at Jun. 30, 2026 0   0 0 0 0        
End of period at Jun. 30, 2026 $ (781,264) (3,567,675) $ 0 $ 0 $ 0 $ 0 $ 99,393,515 6,827,270 (109,788,460) 2,786,411
Common stock, shares outstanding, end of period (in shares) at Jun. 30, 2026 31,727,001           31,727,001      
Preferred stock, shares outstanding, beginning of period (in shares) at Mar. 31, 2026     0 0 0 0        
Beginning of period at Mar. 31, 2026 $ 17,730,060 14,860,984 $ 0 $ 0 $ 0 $ 0 $ 95,332,950 6,440,160 (86,912,126) 2,869,076
Common stock, shares outstanding, beginning of period (in shares) at Mar. 31, 2026             31,539,629      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Issuance of stock (in shares)             183,205      
Issuance of common stock, net of issuance costs and preferred stock 4,048,064 4,048,064         $ 4,048,064      
Issuance of common stock for exercise of warrants (in shares)             4,167      
Issuance of common stock for exercise of warrants 12,501 12,501         $ 12,501      
Issuance of warrants for services 74,659 74,659           74,659    
Issuance of warrants as consideration payable to customer 192,512 192,512           192,512    
Capital distributions to joint venture partners (182,793)                 (182,793)
Stock-based compensation 119,939 119,939           119,939    
Net income (loss) $ (22,776,206) (22,876,334)             (22,876,334) 100,128
Preferred stock, shares outstanding, end of period (in shares) at Jun. 30, 2026 0   0 0 0 0        
End of period at Jun. 30, 2026 $ (781,264) $ (3,567,675) $ 0 $ 0 $ 0 $ 0 $ 99,393,515 $ 6,827,270 $ (109,788,460) $ 2,786,411
Common stock, shares outstanding, end of period (in shares) at Jun. 30, 2026 31,727,001           31,727,001